

May 30, 2019

# **Announcement on Acquisition and Retirement of Own Shares**

(Acquisition of Own Shares pursuant to the Provisions of Article 165, Paragraph 2 of the Companies Act and Retirement of Own Shares pursuant to the Provisions of Article 178 of the Companies Act)

Osaka, Japan, May 30, 2019 - Ono Pharmaceutical Co., Ltd. (President, Representative Director and CEO, Gyo Sagara; "the Company") today announced that in accordance with Article 370 (resolution by documents instead of resolution by board meetings) of the Companies Act, it has resolved to acquire its own shares under the provisions of Article 156 of the Companies Act, applied by the replacing terms pursuant to the provisions of Paragraph 3, Article 165 of the Companies Act, and retire own shares pursuant to the provisions of Article 178 of the Companies Act.

#### **Particulars**

## 1. Reasons for the acquisition and retirement of own shares

The Company will acquire own shares in order to improve capital efficiency and shareholder return, taking into account application status of development products, financial condition, common stock price and other factors.

### 2. Contents of the acquisition

(1) Class of shares to be acquired: Common stock of the Company

(2) Total number of shares to be acquired: 15 million shares (maximum)

(2.92% of the total outstanding shares excluding

treasury shares)

(3) Aggregate amount of acquisition cost: ¥30.0 billion (maximum)

(4) Period of acquisition: May 31, 2019 to September 30, 2019
 (5) Method for acquisition: Purchase on the Tokyo Stock Exchange
 (6) Schedule after acquisition: All the common stock acquired will be retired.

#### 3. Contents of the retirement

(1) Class of shares to be retired: Common stock of the Company

(2) Total number of shares to be retired: All the common stock acquired in accordance with

section 2 above.

(3) Scheduled date of retirement: October 31, 2019 (planned)

(Reference) Number of treasury shares held by the Company as of March 31, 2019

Total number of shares issued (excluding treasury shares): 514,183,401 shares

Total number of treasury shares: 29,157,999 shares

Contact
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
<a href="mailto:public\_relations@ono.co.jp">public\_relations@ono.co.jp</a>